NeoGenomicsNEO +1.27%72 Buyback Yield % is 0.04 as of Jul. 03, 2026. GuruFocus rates NEO with a GF Score™ of 72/100 and a GF Value™ of $16.61 (Fairly Valued). The stock has 6 warning signs investors should review. Among 89 Medical Diagnostics & Research companies, NeoGenomics ranks better than 65.17% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for NeoGenomics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NEO vs WGS, CDNA, PSNL: Buyback Yield % Comparison
For the Diagnostics & Research subindustry, NeoGenomics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeoGenomics Buyback Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, NeoGenomics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where NeoGenomics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeoGenomics (NEO) has a Buyback Yield % of 0.04 as of Jul. 03, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on NeoGenomics and its competitors. According to the industry distribution chart, NeoGenomics ranks #31 out of 89 companies in the Medical Diagnostics & Research industry, placing it in the top 34.8%.
Is NeoGenomics' Buyback Yield % too high?
NeoGenomics' current Buyback Yield % is 0.04. Based on the distribution chart, NeoGenomics ranks #31 out of 89 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, NeoGenomics has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NeoGenomics' Buyback Yield % compare to WGS and CDNA?
According to the Medical Diagnostics & Research industry distribution chart, NeoGenomics ranks #31 out of 89 companies for Buyback Yield %. This puts NeoGenomics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Diagnostics & Research company?
A good Buyback Yield % depends on the Medical Diagnostics & Research industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on NeoGenomics and its competitors. NeoGenomics's current Buyback Yield % is 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeoGenomics stock overvalued right now?
Based on GuruFocus' analysis, NeoGenomics (NEO) is currently considered Fairly Valued. The stock's GF Value™ is $16.61, compared to a current price of $15.17 — trading 8.7% below its estimated fair value. The current Buyback Yield % is 0.04. NeoGenomics' overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For NeoGenomics (NEO), the current Buyback Yield % is 0.04 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NeoGenomics (NEO) Overvalued in 2026?
Based on GuruFocus' analysis, NeoGenomics stock appears to be undervalued.
The current stock price of $15.17 is trading 8.7% below its estimated GF Value™ of $16.61.
GuruFocus considers NeoGenomics to be Fairly Valued.
Key valuation signals for NEO:
Buyback Yield %: 0.04
GF Value™: $16.61 vs. price of $15.17 (8.7% below fair value)
No single metric tells the full story. See the NEO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
72GF Score
Get the complete analysis for NEO
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEO has been successfully added to your 
